Fredun Pharmaceuticals (539730) Q4 24/25 earnings summary

Executive summary

• Board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025, with an unmodified audit opinion on both.

• Final dividend of 7% per equity share (₹0.70 per ₹10 share) recommended, subject to AGM approval.

• Group expanded with the incorporation of Fredun Retail Private Limited and acquisition of One Pet Stop Private Limited, both consolidated for the first time.

Financial highlights

• Standalone revenue for FY25: ₹45,626.82 lakh, up from ₹34,907.18 lakh in FY24.

• Standalone net profit for FY25: ₹2,080.76 lakh, up from ₹1,562.34 lakh in FY24.

• Consolidated revenue for FY25: ₹45,626.85 lakh; consolidated net profit: ₹1,973.93 lakh.

• Q4 FY25 standalone net profit: ₹707.18 lakh, up from ₹533.26 lakh in Q4 FY24.

• EPS (standalone, FY25): ₹44.83 vs. ₹33.32 in FY24; consolidated EPS: ₹44.83.

Outlook and guidance

• Board recommended a final dividend of 7% per equity share, subject to shareholder approval at the AGM.